Discussions on the new molecular formula and new molecular entity definitions of pharmaceutical innovation
Authors:
- 1 November 2018
- journal article
- editorial
- Published by Taylor & Francis in Pharmaceutical Patent Analyst
- Vol. 7 (6) , 235-240
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort studyBMJ, 2015
- Drug patents: the evergreening problemCanadian Medical Association Journal, 2013
- Clinical utility of esomeprazole for treatment of gastroesophageal reflux disease in pediatric and adolescent patientsAdolescent Health, Medicine and Therapeutics, 2012
- PHP163 Pharmaceutical Innovation: Definition, and Mechanisms for RewardValue in Health, 2011
- Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009Clinical Pharmacology & Therapeutics, 2010
- Deconstructing the Drug Development Process: The New Face of InnovationClinical Pharmacology & Therapeutics, 2010
- Lessons from 60 years of pharmaceutical innovationNature Reviews Drug Discovery, 2009
- Pharmaceutical Strategy and Innovation: An Academics PerspectiveChemMedChem, 2007
- The Patents-Based Pharmaceutical Development ProcessJAMA, 2005
- Lenalidomide and Thalidomide: Mechanisms of Action—Similarities and DifferencesSeminars in Hematology, 2005